BMJ Open Diabetes Research & Care

Is non-alcoholic fatty liver disease a sign of left ventricular diastolic dysfunction in patients with type 2 diabetes mellitus? A systematic review and meta-analysis

Sicheng Wang ⁽¹⁾, ¹ Xiangyuan Zhang, ^{1,2} Qiqi Zhang, ¹ Boxun Zhang, ¹ Linhua Zhao ¹

To cite: Wang S, Zhang X, Zhang Q, *et al.* Is non-alcoholic fatty liver disease a sign of left ventricular diastolic dysfunction in patients with type 2 diabetes mellitus? A systematic review and metaanalysis. *BMJ Open Diab Res Care* 2023;**11**:e003198. doi:10.1136/

Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi. org/10.1136/bmjdrc-2022-003198).

bmjdrc-2022-003198

Received 27 October 2022 Accepted 28 January 2023

Check for updates

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Institute of Metabolic Diseases, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China ²Graduate School, Beijing University of Chinese Medicine, Beijing, China

Correspondence to

Linhua Zhao; melonzhao@163.com and Boxun Zhang; 1243876560@qq.com

ABSTRACT

Recent studies have associated non-alcoholic fatty liver disease (NAFLD) with impaired cardiac function. However, patients with type 2 diabetes mellitus (T2DM), a high-risk group for left ventricular diastolic dysfunction (LVDD). were not analyzed as an independent study population. A systematic review was conducted to identify all published clinical trials using the PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, and Wanfang databases from inception to September 14, 2022. Observational studies that reported echocardiographic parameters in T2DM patients with NAFLD compared with those without NAFLD were included for further selection. The Agency for Healthcare Research and Quality checklist was used to appraise the study quality. Ten observational studies (all cross-sectional in design) comprising 1800T2DM patients (1124 with NAFLD, 62.4%) were included. We found that T2DM patients with NAFLD had a significantly lower E/A ratio, higher peak A velocity, higher E/e' ratio, lower e' velocity, greater left atrial maximum volume index, and greater left ventricular mass index than non-NAFLD patients. These findings reinforced the importance of NAFLD being associated with an increased risk of LVDD in the T2DM population, and NAFLD may be a sign of LVDD in patients with T2DM. PROSPERO registration number CRD42022355844.

INTRODUCTION

According to the Diabetes Atlas of the International Diabetes Federation, the number of people with diabetes mellitus (DM) worldwide in 2021 is 537 million, which represents an increase of 74 million (16%) compared with that in 2019, highlighting an astonishing rise in DM prevalence worldwide.¹ Type 2 diabetes mellitus (T2DM) is the most common type of DM and has a profound impact on the cardiovascular system.² Cardiovascular disease (CVD), particularly heart failure (HF), is the leading cause of death in patients with T2DM, which is thought to be due to concurrent coronary artery disease, hypertension, and/

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ The association between non-alcoholic fatty liver disease (NAFLD) and impaired cardiac functions has been demonstrated. However, patients with type 2 diabetes mellitus (T2DM) were not analyzed as an independent population in those studies. This association might be influenced by the synergistic effects of NAFLD and T2DM, which exacerbate myocardial injury.

WHAT THIS STUDY ADDS

⇒ Changes in glycaemic control and the presence of T2DM are crucial for altering cardiac dysfunction. This systematic review and meta-analysis found that NAFLD is associated with an increased risk of LVDD in the T2DM population.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ When NAFLD is diagnosed in patients with diabetes, routine echocardiography should be performed to assess the cardiac diastolic impairment. NAFLD may be a sign of LVDD in patients with T2DM.

or ischemic cardiomyopathy.³ ⁴ However, several studies have shown that myocardial injury can occur independently of traditional CVD risk factors.^{5–7} This condition was defined as diabetic cardiomyopathy (DCM), which primarily leads to left ventricular diastolic dysfunction (LVDD) through increased chamber stiffness and hypertrophy with high resting tension in the early phase, and eventually leads to HF with preserved ejection fraction (HFpEF).^{2 8 9} Thus, the identification and prevention of CVD in patients with T2DM have become an essential issue.

A systematic review of 80 studies has shown that the prevalence of non-alcoholic fatty liver disease (NAFLD) is one of the most pressing health issues globally, reaching 55.5% in patients with T2DM, indicating two times the higher prevalence in the T2DM population than that in the general population.¹⁰ ¹¹ Furthermore, accumulating evidence indicates that NAFLD is strongly associated with an increased risk of cardiac dysfunction, and LVDD is the main phenotype.^{12 13} Owing to the insidious onset of LVDD, cardiac structure and function changes might occur earlier than the symptoms of CVD.¹⁴ Two-dimensional echocardiography using tissue Doppler imaging is the most convenient and reliable diagnostic method for evaluating subclinical changes in cardiac function. In 2016, the American Society of Echocardiography (ASE) and the European Association of Cardiovascular Imaging (EACVI) suggested using routine echocardiographic assessments to evaluate LV diastolic function.¹⁵

Previous meta-analyses have demonstrated an association between NAFLD and impaired cardiac systolic and diastolic functions.¹³ However, patients with T2DM, a high-risk group for NAFLD and LVDD that might lead to HF over time, were not analyzed as an independent population in those studies. This association might be influenced by the synergistic effects of NAFLD and T2DM, which exacerbate myocardial injury. To our knowledge, there has been no systematic review of the association between NAFLD and LVDD in patients with T2DM. Therefore, our meta-analysis aimed to (1) elucidate whether NAFLD is associated with the risk of LVDD via echocardiographic parameters, a relatively objective and detailed assessment, in the T2DM population and (2) explore whether NAFLD is a sign of LVDD in terms of early detection of the risk of developing HFpEF and improving prognosis in patients with T2DM.

MATERIALS AND METHODS

Search strategies and selection criteria

We conducted our systematic review and meta-analysis in accordance with the Meta-analysis of Observational Studies in Epidemiology group guidelines.¹⁶ A comprehensive search strategy was performed to establish our datasets from five electronic databases: PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, and Wanfang. The search was conducted from its inception to September 14, 2022. Using PubMed as an example, medical subject heading terms (eg, NAFLD, DM) and free-text terms (eg, non-alcoholic steatohepatitis, non-alcoholic fatty liver, diabetes) were used in the literature search, and Boolean search terms (OR, AND) were used to merge different knowledge domains. The detailed PubMed retrievals are listed in online supplemental table S1. Because the retrieval rules were similar, retrieval strategies of other databases only needed to be modified based on the retrieval formula of PubMed. Additional relevant documents were manually searched from the reference lists of the included studies, meeting abstracts, and updated systematic reviews to avoid omission. Our study has been registered in the International

Prospective Register of Systematic Reviews (PROSPERO) under the registration number CRD42022355844.

Two investigators (XZ and OZ) independently screened the abstracts or full texts of each publication for eligibility, and any discrepancies were settled through consultation with other authors to obtain more precise data selection. Publications fulfilling the following criteria were included in our meta-analysis: (1) study design: observational studies that were published with no language restriction; potential studies in non-English were translated via translation software; and only fulllength original research studies that were published in peer-reviewed journals were selected. (2) Population: all included participants were adults (≥ 18 years old) with a definite diagnosis of T2DM. (3) Comparison: studies comparing LVDD-related parameters between T2DM patients with NAFLD and those without NAFLD, and the diagnostic criteria of NAFLD were based on invasive liver biopsy or non-invasive diagnostic modalities. (4) Outcomes: the assessment of LVDD from ASE/EACVI guidelines used more than one of the following echocardiographic parameters: peak E velocity (E), peak A velocity (A), mean mitral annular diastolic velocity (e'), E/e' ratio, E/A ratio, deceleration time (DT), LV mass index (LVMI), and left atrial maximum volume index (LA, LAVImax). We excluded studies if (1) they were duplicated; (2) they did not specify the type of DM or only defined NAFLD using blood-based markers; and (3) the same population data were published in different articles.

Quality assessment and data extraction

The risk of bias and methodological quality of each study were evaluated using the Cross-Sectional/Prevalence Study Quality (CSSQ), which is a validated quality scale with a range of 0–11 points for cross-sectional studies, and it was recommended by the Agency for Healthcare Research and Quality (USA). The CSSQ scale contains 11 items, each with three options: "yes" (scored 1), "no" (scored 0), and "unclear" (scored 0), and the maximum CSSQ score of 11 indicates the highest level of study quality.¹⁷

Data from the included articles were extracted directly and separately using a standardized data form in duplicate. Specifically, the main content of the data included study characteristics (authorship, study publication year, study location, study design, and quality assessment score), patient details (sample size, sex proportion, mean age, baseline CVD, and diagnostic modalities for NAFLD), and main outcomes (echocardiographic parameters related to LVDD). For continuous variables, we extracted the mean and SD. If the data in the original study did not conform to the normal distribution, we used the sample size, median, and quartile provided by the authors to estimate the mean and SD using mathematical formulas.^{18 19} Two investigators (XZ and QZ) evaluated and extracted eligible articles independently, and their work was double-checked by a third investigator.

Statistical analysis

The meta-analysis was performed by the meta R package using R Studio (R V.4.2.0). To determine the effect size of each echocardiographic parameter and evaluate the changes in diastolic function in T2DM patients with and without NAFLD, the weighted mean differences (WMD) were calculated along with 95% CIs. Statistical significance was considered for p-value <0.05. Statistical heterogeneity was assessed using Cochrane's Q test and \mathring{I} , and the value of \mathcal{P} indicated whether there was heterogeneity among studies (<25%, 25%-75%, and >75% represent low, moderate, and substantial heterogeneity, respectively).²⁰ All echocardiography parameters were analyzed using random-effects models with a two-tailed statistical comparison, and forest plots were used to visualize the results. Sensitivity analysis with fixed-effects models was conducted to confirm reliability. Additionally, we recalculated the pooled effect estimates by removing each study to further detect the source of heterogeneity. Publication bias was quantitatively examined by conducting Egger's regression test and visually assessed using funnel plots for outcomes with a sufficient sample size $(n \ge 10)$, considering p-value <0.05, a statistically significant bias.²¹

RESULTS

Study identification

Based on our designed search strategy, 412 records were initially identified, and duplicates were removed from the six records. After screening the titles and abstracts, 34 original research articles published in peer-reviewed journals were included for full-text review. Ten studies were included in our meta-analysis based on the previously mentioned eligibility criteria. A detailed flowchart of the search strategy is shown in figure 1.

Study characteristics

Ten observational studies comprising 1800T2DM participants, of which 1124 (62.4%) T2DM with NAFLD were included.²²⁻³¹ We assessed the risk of bias in all eligible studies based on the CSSQ checklist, and all studies achieved scores of 7-9 points (see online supplemental table S2). These observational studies were conducted based on a cross-sectional design, with three retrospective reports and seven prospective reports. In total, five studies were conducted in China (50%), two were conducted in Korea (20%), and one study was performed in Italy, India, and Canada (10%). Overall, the included population was predominantly Asians (80%). As for the diagnostic modalities and evaluation of NAFLD, liver transient elastography was used in two studies, and liver (abdominal) ultrasound was used in eight studies. The main characteristics of the studies are listed in table 1.

NAFLD and the risk of LVDD in patients with T2DM

We conducted our meta-analysis using the eight most commonly indicated echocardiographic parameters. T2DM patients with NAFLD had a significantly lower E/A ratio (WMD: -0.05 (95% CI -0.08 to -0.02); p<0.01), higher peak A velocity (WMD: 2.12 (95% CI 0.11 to 4.14); p<0.05), higher E/e' ratio (WMD: 2.10 (95% CI 1.72 to 2.49); p<0.01), lower e' velocity (WMD: -1.37 (95%




Figure 1 Flowchart of the search strategy and study selection. NAFLD, non-alcoholic fatty liver disease; T2DM, type 2 diabetes mellitus.

6

Table 1 Chara	Table 1 Characteristics of the included studies and participants	s and partic	ipants				
Authorship, Participants published year (n, % of men)	Participants (n, % of men)	Location	Age	Study design	Baseline CVD excluded	Quality score	Modalities for NAFLD diagnosis
Mantovani <i>et</i> al, ²² 2015	T2DM: 64 (85.9%) T2DM+NAFLD: 158 (63.9%)	Italy	T2DM: 66.9±7 T2DM+NAFLD: 68.6±7	Cross-sectional study (prospective)	Yes	ω	Liver ultrasonography
Lee <i>et al,²³ 2021</i>	Lee <i>et al</i> , ²³ 2021 T2DM: 48 (47.9%) T2DM+NAFLD: 83 (60.2%)	Korea	T2DM: 60.8±8.9 T2DM+NAFLD: 60.7±8.9	Cross-sectional study (retrospective)	Yes	0	Liver transient elastography
Chang <i>et al,</i> ²⁴ 2019	T2DM: 30 (73.3%) T2DM+NAFLD: 67 (70.1%)	China	T2DM: 48.5±10 T2DM+NAFLD: 46.3±7.9	Cross-sectional study (prospective)	Yes	7	Liver ultrasonography
Bonapace <i>et</i> al, ²⁵ 2012	T2DM: 18 (72.2%) T2DM+NAFLD: 32 (78.1%)	Canada	T2DM: 63.0±6 T2DM+NAFLD: 64.8±4	Cross-sectional study (prospective)	Yes	2	Liver ultrasonography
Gu <i>et al,²⁶ 2</i> 016	Gu <i>et al</i> , ²⁶ 2016 T2DM: 49 (61.2%) T2DM+NAFLD: 60 (56.7%)	China	T2DM: 57.0±10 T2DM+NAFLD: 55.0±10	Cross-sectional study (prospective)	Yes	ω	Liver transient elastography
Wang <i>et al,<mark></mark>2</i> 2018	T2DM: 40 (52.5%) T2DM+NAFLD: 40 (52.5%)	China	T2DM: 60.8±8.1 T2DM+NAFLD: 64.4±7.9	Cross-sectional study (retrospective)	Yes	ω	Liver ultrasonography
Lee <i>et al,</i> ²⁸ 2020	Lee <i>et al,</i> ²⁸ 2020 T2DM: 251 (27.1%) T2DM+NAFLD: 40 (21.1%)	Korea	T2DM: 63.9±7.3 T2DM+NAFLD: 62.5±6.7	Cross-sectional study (retrospective)	Yes	0	Liver ultrasonography
Yang <i>et al,²⁹</i> 2019	T2DM: 75 (85.3%) T2DM+NAFLD: 178 (64.0%)	China	T2DM: 66.5±8.2 T2DM+NAFLD: 67.8±9.3	Cross-sectional study (prospective)	Yes	ω	Liver ultrasonography
Wang <i>et al</i> , ³⁰ 2020	T2DM: 88 (NA) T2DM+NAFLD: 94 (NA)	China	T2DM: 54.9±6.9 T2DM+NAFLD: 54.6±6.3	Cross-sectional study (prospective)	Yes	7	Liver ultrasonography
Saluja <i>et al</i> , ³¹ 2019	T2DM: 13 (53.8%) T2DM+NAFLD: 57 (54.4%)	India	T2DM: 58.6±11.2 T2DM+NAFLD: 55.1±10.4	Cross-sectional study (prospective)	Yes	7	Liver ultrasonography
CVD, cardiovascu	CVD, cardiovascular disease; NAFLD, non-alcoholic fatty liver disease; T2DM, type 2 diabetes mellitus.	fatty liver dise	ase; T2DM, type 2 diabetes melli	itus.			

Echocardiographic parameters related to LVDD	No of studies	WMD (95% CI)	z	P value	ľ	P value (heterogeneity)
E/A ratio	10	–0.0493 (–0.0827 to –0.0158)	-2.89	0.0039	38.1%	0.1042
Peak E velocity (E)	7	1.7752 (-1.1352 to 4.6856)	1.20	0.2319	70.1%	0.0027
e'	5	-1.3650 (-1.8167 to -0.9132)	-5.92	<0.0001	49.9%	0.0920
Peak A velocity (A)	7	2.1243 (0.1131 to 4.1355)	2.07	0.0384	0.0%	0.9879
E/e' ratio	8	2.1016 (1.7175 to 2.4857)	10.72	<0.0001	46.2%	0.0717
Deceleration time	6	0.4633 (-8.7358 to 9.6624)	0.10	0.9214	47.4%	0.0908
LAVImax	5	2.5761 (1.3404 to 3.8118)	4.09	<0.0001	62.5%	0.0308
LVMI	9	3.7194 (1.9658 to 5.4730)	4.16	<0.0001	0.0%	0.8706

Bold font represents significant differences (p value <0.05).

e', mean mitral annular diastolic velocity ; LAVImax, left atrial maximum volume index; LVDD, left ventricular diastolic dysfunction; LVMI, left ventricular mass index; WMD, weighted mean difference.

CI -1.82 to -0.91); p<0.01), greater LAVImax (WMD: 2.58 (95% CI 1.34 to 3.81); p<0.01), and greater LVMI (WMD: 3.72 (95% CI 1.97 to 5.47); p<0.01) than non-NAFLD patients (table 2, figure 2). In general, compared with that in patients without NAFLD, the risk of incident LVDD was markedly increased in T2DM patients with NAFLD.

Sensitivity analysis

The pooled results of all the sensitivity analyses are shown in online supplemental figure S1. We used fixedeffect models to recalculate the WMD of each diastolicdysfunction-related echocardiographic parameter, which is consistent with our meta-analysis, indicating that our results are not affected by mathematical model selection. We then calculated the overall effect estimates after omitting each study individually to identify potential sources of heterogeneity. The peak E velocity changed significantly after omitting the paper published by Lee et al in 2020. However, the results of the other seven indicators, including E/A and E/e' ratio, were unchanged with moderate or low heterogeneity. In particular, the LVMI and peak A velocity showed no heterogeneity $(\vec{l}=0)$. The risk of publication bias was not detected based on the funnel plot (see online supplemental figure S2) or statistical asymmetry test (p-value=0.6181 for Egger's regression test). Overall, our meta-analysis results were reliable.

DISCUSSION

In the present meta-analysis based on published articles, we synthesized data from 10 cross-sectional designed studies with a total of 1800 participants and proved that T2DM patients with NAFLD were more likely to suffer from LVDD than those without NAFLD. Recently, a comprehensive meta-analysis of 41 studies involving 33891 participants showed that NAFLD is associated with systolic and diastolic impairments.¹³ The authors found that hemoglobin A1c was a predictor of reduced LV ejection fraction (LVEF), and age was a predictor of diastolic dysfunction due to a higher E/e ratio, which showed

their insight into glucose metabolism indicators affecting cardiac function. However, changes in glycemic control and the presence of T2DM are crucial for altering cardiac dysfunction.²

Hence, it is necessary to confirm the association between NAFLD and diastolic dysfunction in the T2DM population, and the assessment of diastolic function according to ASE/EACVI guidelines should have more dimensions.¹⁵ The prevalence of DM is a severe issue in developing countries, and China is the largest developing country with a considerable number of individuals suffering from DM.³² To obtain comprehensive data, we did not restrict the language of the articles to English. To our knowledge, this is the first published meta-analysis to confirm the association between NAFLD and LVDD risk in a T2DM population using echocardiographic parameters.

Specifically, the results of our study showed that, compared with the control group, the NAFLD group had a significantly lower E/A ratio, higher peak A velocity, lower e', higher E/e' ratio, greater LAVImax, and greater LVMI, which collectively indicated an increased risk of LVDD in T2DM patients with NAFLD. The E/A ratio, as an effective, specific, and reproducible transmitral flow index, is often used in multiple large-scale clinical studies to define LVDD.^{33–35} All of our included articles used this index to evaluate cardiac diastolic function, and the results of our meta-analysis also showed a significant statistical difference. However, the E/A ratio has a U-shaped relationship with LV diastolic function, and an abnormally high value can be observed in advanced LVDD.¹⁵

Therefore, to avoid difficulty in distinguishing normal diastolic function from pseudonormal diastolic function, it is indispensable to assess LVDD in combination with other parameters, including tissue Doppler indices. Overall, the more abnormal the parameters, the more suggestive the diagnosis of LVDD.³⁶ The E/e' ratio is an age-dependent Doppler parameter that is positively correlated with the LV filling pressure. Although 8 to

	T2DM + NAFLD	T2DM		
Study Chang-2019	Total Mean SD 67 1.11 0.3100	Total Mean SD 30 1.15 0.3600 -	(1) E/A ratio	MD 95%-CI Weight -0.04 [-0.19; 0.11] 4.2%
Chang-2019 Lee-2020 Wang-2018	355 0.80 0.2200 40 0.78 0.2300	251 0.88 0.3800 40 0.86 0.2200		-0.08 [-0.13; -0.03] 15.8% -0.08 [-0.18; 0.02] 8.0%
Mantovani-2015 Lee-2021	158 0.74 0.2000 83 0.80 0.2000 32 0.72 0.1000	64 0.78 0.2000 48 0.91 0.2900 -		-0.04 [-0.10; 0.02] 14.5% -0.11 [-0.20; -0.02] 8.7%
Bonapace-2012 Wang-2020 Gu-2016	32 0.72 0.1000 94 0.83 0.2300 60 0.99 0.3100	18 0.68 0.1300 88 0.94 0.2400 49 0.97 0.3300		0.04 [-0.03; 0.11] 12.2% -0.11 [-0.18; -0.04] 12.4% 0.02 [-0.10; 0.14] 5.9%
Yang-2019 Saluja-2019	178 0.75 0.3200 57 1.06 0.2700	75 0.79 0.2100 13 1.07 0.1900		-0.04 [-0.11; 0.03] 12.7% -0.01 [-0.13; 0.11] 5.6%
Random effects mo	del 1124 %, $\tau^2 = 0.0011, p = 0.10$	676		-0.05 [-0.08; -0.02] 100.0%
Theorogeneity. 7 = 38	76, t = 0.0011, p = 0.10	-0.2 Wei	2 -0.1 0 0.1 0 ght Mean Difference (95%)	0.2 CI)
Study	T2DM + NAFLD Total Mean SD	T2DM Total Mean SD	(2) Peak E velocity (cm/s) MD 95%–CI Weight
Lee-2020 Mantovani-2015	355 66.00 15.0000 158 66.90 15.0000	251 70.00 17.0000 64 62.70 17.0000		-4.00 [-6.62; -1.38] 19.8% 4.20 [-0.58; 8.98] 14.4%
Lee-2021 Bonapace-2012 Gu-2016	83 60.00 10.0000 32 64.00 12.0000 60 72.00 16.0000	48 60.00 10.0000 18 57.00 16.0000 49 69.00 17.0000		0.00 [-3.55; 3.55] 17.4% - 7.00 [-1.48; 15.48] 7.9% 3.00 [-3.25; 9.25] 11.3%
Yang-2019 Saluja-2019	178 66.48 14.8100 57 80.00 10.0000	75 63.09 16.7200 13 76.00 8.0000		3.39 [-0.97; 7.75] 15.4% 4.00 [-1.06; 9.06] 13.8%
Random effects mode Heterogeneity: $I^2 = 70\%$	1923	518		1.78 [-1.14; 4.69] 100.0%
Heterogeneity: T = 70%	$\tau = 9.3485, p < 0.01$		5 -10 -5 0 5 10 eight Mean Difference (95%	15 6 CI)
Study	T2DM + NAFLD Total Mean SD	T2DM Fotal Mean SD	(3) Mean e' (cm/s)	MD 95%-CI Weight
Chang-2019	67 11.70 2.9100	30 13.55 2.4700 -		-1.85 [-2.98; -0.72] 11.6%
Mantovani-2015 Bonapace-2012 Gu-2016	158 7.60 1.7000 32 8.20 1.5000 60 6.90 2.4000	64 9.30 1.9000 18 9.90 1.9000 - 49 7.30 2.0000		-1.70 [-2.24; -1.16] 26.0% -1.70 [-2.72; -0.68] 13.3% -0.40 [-1.23; 0.43] 17.3%
Saluja-2019	57 8.42 0.8900	13 9.72 0.5400	+	-1.30 [-1.67; -0.93] 32.0%
Random effects mode Heterogeneity: $I^2 = 50\%$	374 $\tau^2 = 0.1299, p = 0.09$	174	<u> </u>	-1.36 [-1.82; -0.91] 100.0%
	TADMANAPID	Wei T2DM	-2 -1 0 1 2 ght Mean Difference (95%	6 CI)
Study	T2DM + NAFLD Total Mean SD	Total Mean SD	(4) Peak A velocity (cm	
Lee-2020 Mantovani-2015	355 85.00 17.0000 158 81.60 33.0000	251 83.00 18.0000 64 79.20 14.0000	_ 	2.00 [-0.84; 4.84] 50.0% 2.40 [-3.78; 8.58] 10.6% 0.00 [-7.11] 7.11] 8.0%
Lee-2021 Bonapace-2012 Gu-2016	83 70.00 20.0000 32 89.00 13.0000 60 76.00 16.0000	48 70.00 20.0000 18 84.00 16.0000 49 74.00 17.0000		$\begin{array}{cccccccccccccccccccccccccccccccccccc$
Yang-2019 Saluja-2019	178 81.39 32.2700 57 76.00 19.0000	75 79.47 16.3600 13 72.00 15.0000		1.92 [-4.10; 7.94] 11.2%
Random effects mode Heterogeneity: $I^2 = 0\%$,	$\frac{1}{\tau^2} = 0$ $p = 0.99$	518	· · · · · ·	2.12 [0.11; 4.14] 100.0%
newogeneny. 1 – 076,	<i>v</i> = 0, <i>p</i> = 0.33	W.	-10 -5 0 5 1 Veight Mean Difference (95	
Study	T2DM + NAFLD Total Mean SD	T2DM Total Mean SD	(5) E/e' ratio	MD 95%-CI Weight
Chang-2019	Total Mean SD 67 10.20 2.7000	Total Mean T2DM 30 7.60 2.0000		-2.60 [1.64; 3.56] 10.3%
Chang-2019 Wang-2018 Mantovani-2015 Lee-2021	Total Mean SD 67 10.20 2.7000 40 8.86 2.5400 158 9.60 2.0000 83 10.60 3.2000	Total Mean T2DM SD 30 7.60 2.0000 40 7.67 2.7400 64 6.90 2.0000 48 9.30 3.7000		2.60 [1.64; 3.56] 10.3% 1.19 [0.03; 2.35] 8.0% 2.70 [2.12; 3.28] 17.6% 1.30 [0.05; 2.55] 7.1%
Chang-2019 Wang-2018 Mantovani-2015 Lee-2021 Bonapace-2012 Gu-2016	Total Mean SD 67 10.20 2.7000 40 8.86 2.5400 158 9.60 2.0000 83 10.60 3.2000 32 7.90 1.3000 60 11.10 3.3000	Total Mean T2DM SD 30 7.60 2.0000 40 7.67 2.7400 64 6.90 2.0000 48 9.30 3.7000 18 5.59 1.1000 49 10.00 3.2000		
Chang-2019 Wang-2018 Mantovani-2015 Lee-2021 Bonapace-2012	Total Mean SD 67 10.20 2.7000 40 8.86 2.5400 158 9.60 2.0000 83 10.60 3.2000 32 7.90 1.3000	Total Hean T2DM SD 30 7.60 2.0000 40 7.67 2.7400 64 6.90 2.0000 48 9.30 3.7000 18 5.59 1.1000		$\begin{array}{c}2.60 & [1.64; 3.56] & 10.3\% \\ 1.19 & [0.03; 2.35] & 8.0\% \\2.70 & [2.12; 3.28] & 17.6\% \\1.30 & [0.05; 2.55] & 7.1\% \\2.31 & [1.63; 2.99] & 15.4\% \end{array}$
Chang-2019 Wang-2018 Mantovani-2015 Lee-2021 Bonapace-2012 Gu-2016 Yang-2019	Total Mean SD 67 10.20 2.7000 40 8.86 2.5400 158 9.60 2.0000 83 10.60 3.2000 32 7.90 1.3000 60 11.10 3.3000 178 9.50 2.1100 57 9.64 1.8300 el 675 -	Total Mean T2DM SD 30 7.60 2.0000 40 7.67 2.7400 64 6.90 2.0000 48 9.30 3.7000 18 5.59 1.1000 49 10.00 3.2000 75 7.12 1.9200	(5) E/e' ratio	$\begin{array}{c c c c c c c c c c c c c c c c c c c $
Chang-2019 Wang-2018 Mantovani-2015 Lee-2021 Bonapace-2012 Gu-2016 Yang-2019 Saluja-2019 Random effects mod	Total Mean SD 67 10.20 2.7000 40 8.86 2.5400 158 9.60 2.0000 83 10.60 3.2000 60 1.100 3.2000 70 9.62 2.0001 82 5.9 1.3000 60 11.10 3.3000 178 9.50 2.1100 57 9.64 1.8300 el 675 $\epsilon_{11301, p} = 0.07$	Total Mean T2DM SN 30 7.60 2.000 40 7.67 2.7400 64 6.90 2.0000 8 9.30 3.7000 18 5.59 1.1000 90 0.00 3.2000 75 7.12 1.9200 13 7.78 0.8900		- 2.60 [1.64; 3.56] 10.3% 1.19 [0.03; 2.35] 8.0% - 2.70 [2.12; 3.28] 17.6% - 1.30 [0.05; 2.55] 7.1% - 2.31 [1.63; 2.99] 15.4% 1.10 [-0.12; 2.22] 7.4% 1.86 [1.18; 2.54] 15.4% 2.30 [1.18; 2.54] 15.4% 2.31 [1.5; 2.4] 100.0% 3
Chang-2019 Wang-2018 Mantovani-2015 Lee-2021 Bonapace-2012 Gu-2016 Yang-2019 Random effects mod Heterogeneity: I ² = 469	Total Mean SD 67 10.20 2.7000 40 8.6 2.5400 158 9.60 2.0000 83 10.60 3.2000 32 7.90 1.3000 60 11.10 3.2000 57 9.64 1.8300 el 675 6, e ² = 0.1301, p = 0.07 T2DM + NAFLD 72	Total Mean T2DM SD 30 7.60 2.0000 40 7.67 2.7400 64 6.90 2.0000 8 9.30 3.7000 18 5.59 1.1000 9 10.00 3.2000 75 7.12 1.9200 13 7.78 0.8900	(5) E/e' ratio	$\begin{array}{c} -2.60 & [1.64; 3.56] & 10.3\% \\ 1.19 & [0.03; 2.53] & 8.0\% \\ -2.70 & [2.12; 3.28] & 17.6\% \\ -3.20 & [2.12; 3.28] & 17.6\% \\ -1.30 & [0.05; 2.55] & 7.1\% \\ -2.31 & [1.63; 2.99] & 15.4\% \\ -2.38 & [1.85; 2.91] & 18.8\% \\ -1.86 & [1.18; 2.54] & 15.4\% \\ \hline 2.10 & [1.72; 2.49] & 100.0\% \\ 3 \\ 3 \\ \% \text{ CI} \end{array}$
Chang-2019 Wang-2018 Mantovani-2015 Lee-2021 Bonapace-2012 Gu-2016 Yang-2019 Saluja-2019 Random effects mod Heterogeneity: I ² = 46% Study Lee-2020 Mantovani-2015	Total Mean SD 67 10.20 2.7000 40 8.62 5.400 15.8 9.60 2.0000 83 10.60 3.2000 32 7.90 1.3000 60 11.10 3.2000 57 9.64 1.8300 el 675 6, e ² f 1.010, p 0.07 57 5.64 1.8300 el 675 3.52 52.55.90 44.4000 3.55 158 256.60 60.000	Total Mean T2DM SD 30 7.60 2.0000 40 7.67 2.7400 64 6.90 2.0000 8 9.30 3.0700 18 5.59 1.1000 49 10.00 3.2000 75 7.12 1.9200 13 7.78 0.8900 337 W V Colspan="2">W Colspan="2">Colspan="2">Colspan="2" 2.12 M Colspan="2">Colspan="2" 2.51 2.51 48.80 2.51 2.51 2.51 Colspan="2" 2.51 Colspan="2"	(5) E/e' ratio	-2.60 [1.64; 3.56] 10.3% 1.19 [0.03; 2.35] 8.0% -2.70 [2.12; 3.28] 17.6% -1.30 [0.05; 2.55] 7.1% -2.31 [1.63; 2.99] 15.4% 1.10 [-0.12; 2.32] 7.4% -2.38 [1.85; 2.91] 18.8% -2.38 [1.85; 2.91] 10.0% -3.8% CI) -2.10 [1.72; 2.49] 100.0% -3.8% CI) -2.10 [0.56; 15.64] 33.2% -1.100 [0.56; 15.64] 33.2% -1.100 [0.56; 15.64] 33.2%
Chang-2019 Wang-2018 Mantovani-2015 Lee-2021 Bonapace-2012 Gu-2016 Yang-2019 Saluja-2019 Random effects mod Heterogeneity: I ² = 46% Study Lee-2020 Mantovani-2015 Lee-2021 Bonapace-2012	Total Mean SD 67 10.20 2.7000 40 8.86 2.5400 158 9.60 2.0000 83 16.60 3.2000 83 16.60 2.0000 83 16.60 2.0000 84 10.60 2.0100 78 9.50 2.1100 57 9.64 1.8300 el 675 6, e ² = 0.07 Total Mean SD 1 355 256.90 44.4000 158 250.40 60.0000 82 210.20 37.0000 32 210.20 37.0000	Total Hern T2DM SD 30 7.60 2.0000 40 7.67 2.7400 64 6.90 2.0000 8 9.30 3.7000 18 5.59 1.1000 9 10.00 3.2000 75 7.12 1.9200 13 7.78 0.8900 337 W V Colspan="2">W Colspan="2">Colspan="2">Colspan="2" A Colspan="2" V V Colspan="2" Colspan="2" V Colspan="2" Colspan="2" V V V V V Colspan="2" Colspan="2" Colspan="2"	(5) E/e' ratio	-2.60 [1.64; 3.56] 10.3% 1.19 [0.03; 2.35] 8.0% -2.70 [2.12; 3.28] 17.6% -1.30 [0.05; 2.55] 7.1% -2.31 [1.63; 2.99] 15.4% 1.10 [-0.12; 2.32] 7.4% -2.38 [1.85; 2.91] 18.8% -2.38 [1.85; 2.91] 18.8% -2.38 [1.85; 2.91] 18.8% -3.38 [1.85; 2.91] 18.8% -3.38 [1.85; 2.91] 18.8% -3.38 [1.85; 2.91] 10.0% -3.38 [1.85; 2.91] 10.0%
Chang-2019 Wang-2018 Mantovani-2015 Lee-2021 Bonapace-2012 Gu-2016 Saluja-2019 Random effects mod Heterogeneity: J ² = 46% Study Lee-2020 Mantovani-2015 Lee-2021 Bonapace-2012 Bonapace-2012 Saluja-2019	Total Mean SD 67 10.20 2.7000 40 8.86 2.5400 158 9.60 2.0000 83 10.60 3.2000 83 10.60 3.2000 60 1.10 3.3000 61 1.10 3.3000 62 1.600 1.8300 61 5.7 9.64 1.8300 61 5.7 0.101, $p = 0.07$ 1.00 73 5.5 5.60 44 000 158 250.40 66 000 32 233.20 70000 32 233.20 70000 32 233.20 70000 32 232.20 70000 32 232.20 70000 32 233.20 70 000 32 232.20 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26 <	Total Mean T2DM SN 30 7.60 2.000 40 7.67 2.7400 64 6.90 2.000 78 2.000 3.700 18 5.59 1.100 49 10.00 3.2000 75 7.12 1.9200 13 7.78 0.8900 337 W Value Value 1000 48 2.4300 48 2.4300 52 2.48.08 48.2000 64 61.40 61.0000 75 2.62.31 62.4300 18 25.340 52.0000 18 25.340 52.4300 13 2.05.29 3.3300	(5) E/e' ratio	$\begin{array}{c} -2.60 & [1.64; 3.56] & 10.3\% \\ 1.19 & [0.03; 2.53] & 8.0\% \\ -2.70 & [2.12; 3.28] & 17.6\% \\ -3.30 & [0.05; 2.55] & 7.1\% \\ -2.31 & [1.63; 2.99] & 15.4\% \\ -2.38 & [1.85; 2.91] & 18.8\% \\ -2.38 & [1.85; 2.94] & 18.8\% \\ -2.38 & [1.85; 2.94] & 18.8\% \\ -2.38 & [1.85; 2.94] & 15.4\% \\ -2.38 & [1.85; 2.94] & 15.4\% \\ -2.38 & [1.85; 2.94] & 15.4\% \\ -2.10 & [1.72; 2.49] & 100.0\% \\ -3.35\% CI) \\ \end{array}$
Chang-2019 Wang-2018 Mantovani-2015 Lee-2021 Bonapace-2012 Gu-2016 Saluja-2019 Random effects mod Heterogeneity: J ² = 46% Study Lee-2020 Mantovani-2015 Lee-2021 Bonapace-2012 Bonapace-2019	Total Mean SD 67 10.20 2.7000 40 8.86 2.5400 158 9.60 2.0000 83 10.60 3.2000 83 10.60 3.2000 60 1.10 3.3000 61 1.10 3.3000 62 1.600 1.8300 61 5.7 9.64 1.8300 61 5.7 0.101, $p = 0.07$ 1.00 73 5.5 5.60 44 000 158 250.40 66 000 32 233.20 70000 32 233.20 70000 32 233.20 70000 32 232.20 70000 32 232.20 70000 32 233.20 70 000 32 232.20 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26 <	Total Mean T2DM SN 30 7.60 2.000 40 7.67 2.7400 64 6.90 2.0000 18 5.59 1.1000 49 10.00 3.2000 75 7.12 1.9200 13 7.78 0.8900 337 W Val Call 1.0 61.40 61.000 S0 62 2.21 75 2.62.31 62.400 75 2.62.31 62.4000 75 2.62.31 62.4000 73 2.52.340 56.000 75 2.62.31 62.4000 18 25.340 56.2000 18 25.340 56.2000 13 2.55 3.9380 469 14.000 1.9200	(5) E/e' ratio	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
Chang-2019 Wang-2018 Mantovani-2015 Lee-2021 Bonapace-2012 Gu-2016 Saluja-2019 Random effects mod Heterogeneity: J ² = 46% Study Lee-2020 Mantovani-2015 Lee-2021 Bonapace-2012 Bonapace-2012 Saluja-2019	Total Mean SD 67 10.20 2.7000 40 8.86 2.5400 158 9.60 2.0000 83 10.60 3.2000 90 1.3000 60 11.10 3.3000 97 9.64 1.8300 1.8300 el 675 6, e ² = 0.1301, p = 0.07 1.852 526, 90 44, 4000 158 256, 90 44, 4000 832 10.20 370000 158 256, 90 44, 4000 832 23.102 370000 178 25.12 67 2600 173 2.212, 20 172 25.12 67 2600 174 3.000 178 25.12 67 2600 174 21.26 147,3400 263 27 21.26 147,3400 174 251.12 174	Total T2DM (Marchine) T2DM (Marchine) 30 7.60 2.000 40 7.67 2.7400 64 6.30 2.0000 18 5.59 1.1000 49 10.00 3.2000 75 7.12 1.9200 337 337 W Val Cold Cold Cold 42 1.49 0.000 75 7.12 337 W W W W 51 2.48.40 48 2.000 75 64 2.14.40 61.0000 75 2.02 75 2.62.31 62.4000 75 2.62 18 2.53.40 56.0000 13 2.93.9800 13 2.55.92 3.93.8000 13 2.55.93 3.93.800	(5) E/e' ratio	$\begin{array}{c} -2.60 & [1.64; 3.56] & 10.3\% \\ 1.19 & [0.03; 2.35] & 8.0\% \\ -2.70 & [2.12; 3.28] & 17.6\% \\ 1.30 & [0.05; 2.55] & 7.1\% \\ -2.31 & [1.63; 2.99] & 15.4\% \\ 1.10 & [-0.12; 3.22] & 7.4\% \\ -2.38 & [1.85; 2.91] & 18.8\% \\ -2.38 & [1.85; 2.91] & 18.8\% \\ -2.38 & [1.85; 2.94] & 15.4\% \\ 1.86 & [1.18; 2.54] & 15.4\% \\ -2.38 & [1.85; 2.94] & 100.0\% \\ 3 \\ 3 \\ 3 \\ 5\% CT) \\ \end{array}$
Chang-2019 Wang-2018 Mantovani-2015 Lee-2021 Bonapace-2012 Giu-2016 Saluja-2019 Random effects mod Heterogeneity: I ² = 46% Study Lee-2020 Mantovani-2015 Lee-2021 Bonapace-2012 Yang-2019 Saluja-2019 Random effects model Heterogeneity: I ² = 47%, ,	Total Mean SD 67 10.20 2.7000 40 8.86 5.400 158 9.60 2.0000 82 7.90 1.3000 60 110.03 3.000 178 9.50 2.1100 57 9.64 1.8300 el 675 7 752.04 NAFLD Total Mean 352 350.40 66 352 350.40 960 35 350.40 960 35 256 72.00 362 37.0000 32 32 10.20 70000 32 323.07 78 32 10.20 74.000 863 $e^2 = 51.6235, p = 0.09$ TOtal Mean Total Mean	Total Table Table 30 7.60 2.0000 40 7.67 2.7400 64 6.90 2.0000 75 7.12 1.9200 18 5.59 1.1000 49 10.00 3.2000 75 7.12 1.9200 13 7.78 0.8900 337	(5) E/e' ratio	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
$\label{eq:chang-2019} \\ \mbox{Wang-2018} \\ \mbox{Wang-2018} \\ \mbox{Manicovani-2015} \\ \mbox{Lec-2021} \\ \mbox{Bonapace-2012} \\ \mbox{Gaussian} \\ \mbox{Study} \\ \mbox{Lec-2020} \\ \mbox{Manicovani-2015} \\ \mbox{Lec-2021} \\ \mbox{Bonapace-2019} \\ \mbox{Random effects model} \\ \mbox{Heterogeneity: } I^2 = 46\% \\ \mbox{Study} \\ \mbox{Lec-2021} \\ \mbox{Random effects model} \\ \mbox{Heterogeneity: } I^2 = 47\%, \end{tabular}$	Total Mean SD 67 10.20 2.7000 40 8.86 5.400 158 9.60 2.0000 82 7.90 1.3000 60 110.03 3.000 178 9.50 2.1100 57 9.64 1.8300 el 675 5.6 55 55.60 \$44,000 158 350.40 66<0000	Total T2DM (March Mean T2DM SD 30 7.60 2.0000 40 7.67 2.7400 64 6.90 2.0000 8 9.30 3.000 18 5.59 1.1000 9 10.00 3.2000 75 7.12 1.9200 13 7.78 0.8900 337 Call Call 64 2.61.40 61.0000 62 1.48 80 42.000 64 2.14.90 12.000 18 253.40 75 2.62 31.2000 18 254.90 12 2.05.92 39.3800 469 469 Call Call Call SD 75 2.62 3.93.800 SD SD 469 Call Call SD SD 7 Call Mean SD SD 9 O 2.72.1 2.4200 SD	(5) E/e' ratio	$\begin{array}{c} -2.60 & [1.64; 3.56] & 10.3\% \\ 1.19 & [0.03; 2.35] & 8.0\% \\ -2.70 & [2.12; 3.28] & 17.6\% \\ -2.70 & [2.12; 3.28] & 17.6\% \\ -2.31 & [1.63; 2.99] & 15.4\% \\ 1.10 & [-0.12; 3.22] & 7.4\% \\ -2.38 & [1.85; 2.91] & 18.8\% \\ -2.38 & [1.85; 2.94] & 18.8\% \\ -2.38 & [1.85; 2.94] & 18.8\% \\ -2.38 & [1.85; 2.94] & 15.4\% \\ -2.38 & [1.85; 2.94] & 15.4\% \\ -2.10 & [1.72; 2.49] & 100.0\% \\ -3.86 & [1.16; 2.54] & 33.2\% \\ -11.00 & [-2.95; 7.15] & 16.0\% \\ -4.70 & [-21.23; 11.83] & 17.9\% \\ -2.98 & [-7.61; 67.21] & 5.3\% \\ -11.09 & [-2.83; 6.15] & 17.1\% \\ 6.69 & [-17.99; 31.37] & 10.5\% \\ 0.46 & [-8.74; 9.66] & 100.0\% \\ 0 \\ CI) \\ \hline \begin{array}{c} \text{MD} & 95\%-CI & Weight \\ -3.87 & [2.77; 4.97] & 28.5\% \\ 2.20 & [0.58; 3.82] & 22.6\% \\ \end{array}$
Chang-2019 Wang-2018 Mantovani-2015 Lee-2021 Bonapace-2012 Giu-2016 Yang-2019 Saluja-2019 Random effects model Heterogeneity: $I^2 = 469$ Study Lee-2020 Mantovani-2015 Lee-2021 Yang-2019 Saluja-2019 Random effects model Heterogeneity: $I^2 = 47\%$, s Study Chang-2019	Total Mean SD 67 10.20 2.7000 40 8.86 2.5400 158 9.60 2.0000 83 10.60 3.2000 32 7.90 1.3000 60 11.10 3.2000 32 7.90 1.3001 78 9.50 2.1000 57 9.64 1.8300 el 675 6, e ² = 0.1301, p = 0.07 55 256.90 44.4000 158 256.90 80000 178 2.510.20 37.0000 32 283.20 78.0000 32 23.12.20 67.2000 57 21.26.1 47.3400 863 2 ² = 51.6235, p = 0.09 9 T2DM + NAFLIL Total Mean SI 21.22 67.2000 57 57 21.26.1 47.3400 863 2 ² = 51.6235, p = 0.09 9 172DM + NAFLIL SI	Total T2DM Mem T2DM SD 30 7.60 2.0000 40 7.67 2.7400 64 6.90 2.0000 75 7.210 2.0000 75 7.12 1.9200 13 7.78 0.8900 337	(5) E/e' ratio	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
$\label{eq:changerout} \begin{split} & \text{Changerout}\\ & \text{Wangerout}\\ & \text{Wandowani-2015}\\ & \text{Lee-2021}\\ & \text{Bonapace-2012}\\ & \text{Giu-2016}\\ & \text{Yang-2019}\\ & \text{Saluja-2019}\\ & \text{Saluja-2019}\\ & \text{Random effects model}\\ & \text{Heterogeneity:} I^2 = 46\%\\ & \text{Study}\\ & \text{Lee-2020}\\ & \text{Wantowani-2015}\\ & \text{Lee-2020}\\ & \text{Wantowani-2015}\\ & \text{Lee-2021}\\ & \text{Bonapace-2012}\\ & \text{Yang-2019}\\ & \text{Study}\\ & \text{Chang-2019}\\ & \text{Lee-2021}\\ & \text{Bonapace-2012}\\ & \text{Yang-2019}\\ & \text{Saluja-2019}\\ & \text{Random effects model}\\ & Random effec$	Total Mean SD 67 10.20 2.7000 40 8.86 2.5400 158 9.60 2.0000 83 10.60 3.2000 83 10.60 3.2000 93 7.90 1.3000 60 11.10 3.2000 97 9.64 1.8300 el 675 6.75 6, $e^2 = 0.1301, p = 0.07$ 7 7.64 Total Mean SD 7 355 256.90 44.4000 32 28.320 80000 32 28.320 80000 32 28.320 80000 32 28.320 80000 32 28.320 80000 32 28.320 80000 32 28.320 80000 32 28.300 8000 32 28.300 10.800 32 27.400 800 32 27.400 10.300	Total T2DM Mem T2DM SD 30 7.60 2.0000 40 7.67 2.7400 64 6.90 2.0000 75 7.210 2.0000 75 7.12 1.9200 13 7.78 0.8900 337	(5) E/e' ratio	2.60 [1.64; 3.56] 10.3% 1.19 [0.03; 2.35] 8.0% 2.70 [2.12; 3.28] 17.6% 2.30 [0.05; 2.55] 7.1% 2.31 [1.63; 2.99] 15.4% 2.33 [1.63; 2.99] 15.4% 2.38 [1.85; 2.91] 18.8% 1.86 [1.18; 2.54] 15.4% 2.10 [1.72; 2.49] 100.0% 3. 3. 3. 3. 3. 3. 4. 5. MD 95%-CI Weight 8.10 [0.56; 15.64] 33.2% -11.00 [-29.15; 7.15] 16.0% -4.70 [-21.23; 11.83] 17.9% -2.98 [-7.61; 67.21] 5.3% -11.09 [-28.33; 6.15] 17.1% 6.69 [-17.99; 31.37] 10.5% 0.46 [-8.74; 9.66] 100.0% 0. CI) MD 95%-CI Weight - 3.87 [2.77; 4.97] 28.5% 2.20 [0.58; 3.82] 22.6% 2.20 [0.46; 3.82] 22.6% 2.20 [0.46; 5.3%] - 3.20 [0.44; 5.46] 16.5%
$\label{eq:constraint} \begin{split} & \text{Chang-2019} \\ & \text{Wang-2018} \\ & \text{Manitovani-2015} \\ & \text{Lec-2021} \\ & \text{Bonapace-2012} \\ & \text{Gin-2016} \\ & \text{Satuja-2019} \\ \hline \\ & \text{Random effects model} \\ & \text{Heterogeneity: } I^2 = 46\% \\ \hline \\ & \text{Study} \\ & \text{Lec-2020} \\ & \text{Mantovani-2015} \\ & \text{Lec-2021} \\ & \text{Bonapace-2012} \\ & \text{Sangace-2012} \\ & \text{Yang-2019} \\ & \text{Satuja-2019} \\ & \text{Random effects model} \\ & \text{Heterogeneity: } I^2 = 47\%, \tau \\ \hline \\ & \text{Study} \\ \hline \\ & \text{Chang-2019} \\ & \text{Lec-2021} \\ & \text{Bonapace-2019} \\ & \text{Lec-2021} \\ & \text{Bonapace-2019} \\ & \text{Lec-2021} \\ & \text{Bonapace-2019} \\ & \text{Satuja-2019} \\ & \text{Satuja-2019} \\ \hline \\ & \text{Satuja-2019} \\ & \text{Satuja-2019} \\ \hline \\ \hline \\ & \text{Satuja-2019} \\ \hline \\ & \text{Satuja-2019} \\ \hline \\ \hline \\ \hline \\ \hline \\ \hline \\ \\ \hline \\ \hline \\ \hline \\ \hline $	Total Mean SD 67 10.20 2.7000 40 8.86 2.5400 158 9.60 2.0000 83 10.60 3.2000 83 10.60 3.2000 93 7.90 1.3000 60 11.10 3.2000 97 9.64 1.8300 el 675 6.75 6, $e^2 = 0.1301, p = 0.07$ 7 7.64 Total Mean SD 7 355 256.90 44.4000 32 28.320 80000 32 28.320 80000 32 28.320 80000 32 28.320 80000 32 28.320 80000 32 28.320 80000 32 28.320 80000 32 28.300 8000 32 28.300 10.800 32 27.400 800 32 27.400 10.300	Total Mean T2DM SN 30 7.60 2.0000 40 7.67 2.7400 64 6.90 2.0000 75 7.12 1.9200 337 3.778 0.8900 337 3.778 0.8900 337 2.000 75 7.12 307 2.020 3.9700 1.900 337 3.900 3.900 1.900 337 3.900 3.900 1.900 319 2.020 3.900 1.900 18 3.05 3.900 1.900 25.92 3.9200 3.900 1.900 18 2.540 5.900 4.900 13 2.523 3.9300 1.900 469 3.900 1.900 1.900 469 3.900 2.900 1.900 13 2.520 3.9200 1.900 148 2.600 4.900 1.900 148 3.	(5) E/e' ratio	$\begin{array}{c} -2.60 & [1.64; 3.56] & 10.3\% \\ 1.19 & [0.03; 2.35] & 8.0\% \\ -2.70 & [2.12; 3.28] & 17.6\% \\ 1.30 & [0.05; 2.55] & 7.1\% \\ -2.31 & [1.63; 2.99] & 15.4\% \\ 1.10 & [-0.12; 2.32] & 7.4\% \\ -2.38 & [1.85; 2.91] & 18.8\% \\ -3.38 & [1.85; 2.91] & 18.8\% \\ -1.86 & [1.18; 2.54] & 15.4\% \\ -1.86 & [1.18; 2.54] & 15.4\% \\ -2.38 & [1.85; 2.91] & 100.0\% \\ -3.\% & CI) \\ \end{array}$
$\label{eq:changerout} \begin{split} & \text{Changerout}\\ & \text{Wangerout}\\ & \text{Wandowani-2015}\\ & \text{Lee-2021}\\ & \text{Bonapace-2012}\\ & \text{Giu-2016}\\ & \text{Yang-2019}\\ & \text{Saluja-2019}\\ & \text{Saluja-2019}\\ & \text{Random effects model}\\ & \text{Heterogeneity:} I^2 = 46\%\\ & \text{Study}\\ & \text{Lee-2020}\\ & \text{Wantowani-2015}\\ & \text{Lee-2020}\\ & \text{Wantowani-2015}\\ & \text{Lee-2021}\\ & \text{Bonapace-2012}\\ & \text{Yang-2019}\\ & \text{Study}\\ & \text{Chang-2019}\\ & \text{Lee-2021}\\ & \text{Bonapace-2012}\\ & \text{Yang-2019}\\ & \text{Saluja-2019}\\ & \text{Random effects model}\\ & Random effec$	Total Mean SD 67 10.20 2.7000 40 8.86 2.5400 158 9.60 2.0000 82 7.90 1.3000 60 11.10 3.3000 178 9.50 2.1100 57 9.64 1.8300 el 675 7 752 255.09 44.000 158 250.40 158 250.40 66.0000 82 210.20 37.0000 152 255.09 44.000 158 250.40 60.0000 32 283.20 78.0000 178 29.02 37.0000 75 72.12.41 73.400 80.000 178 251.22 67.2000 263 22.83.02 49.000 178 251.22 67.2000 178 21.20 18.000 188 250.40 60.000 83 22.83.02 80.000 178 21.22 74.00 188.00 188.200 178.82.80 18.92.00	Total Mean T2DM SN 30 7.60 2.0000 40 7.67 2.7400 64 6.90 2.0000 75 7.12 1.9200 337 3.778 0.8900 337 3.778 0.8900 337 2.000 75 7.12 307 2.020 3.9700 1.900 337 3.900 3.900 1.900 337 3.900 3.900 1.900 319 2.020 3.900 1.900 18 3.05 3.900 1.900 25.92 3.9200 3.900 1.900 18 2.540 5.900 4.900 13 2.523 3.9300 1.900 469 3.900 1.900 1.900 469 3.900 2.900 1.900 13 2.520 3.9200 1.900 148 2.600 4.900 1.900 148 3.	(5) E/e' ratio	$\begin{array}{c} -2.60 & [1.64; 3.56] & 10.3\% \\ 1.19 & [0.03; 2.35] & 8.0\% \\ -2.70 & [2.12; 3.28] & 17.6\% \\ 1.30 & [0.05; 2.55] & 7.1\% \\ -2.31 & [1.63; 2.99] & 15.4\% \\ 1.10 & [-0.12; 2.32] & 7.4\% \\ -2.38 & [1.85; 2.91] & 18.8\% \\ -3.38 & [1.85; 2.91] & 18.8\% \\ -1.86 & [1.18; 2.54] & 15.4\% \\ -1.86 & [1.18; 2.54] & 15.4\% \\ -2.38 & [1.85; 2.91] & 100.0\% \\ -3.\% & CI) \\ \end{array}$
Chang=2019 Wang=2018 Manitovani=2015 Lee=2021 Bonapace=2012 Git=2016 Yang=2019 Random effects model Heterogeneity: $I^2 = 469$ Study Lee=2020 Manitovani=2015 Lee=2020 Manitovani=2019 Random effects model Heterogeneity: $I^2 = 47\%$, t^2 Study Chang=2019 Study Chang=2019 Random effects model Heterogeneity: $I^2 = 62\%$ Study Lee=2020	Total Mean SD 67 10.20 2.7000 40 8.86 2.5400 158 9.60 2.0000 82 7.90 1.3000 60 11.03 3.000 79 9.50 2.1100 57 9.64 1.8300 el 675 5. 6., $r^2 = 0.1301, p = 0.07$ 3.55 2.50.40 702DM + NAFLD 3.55 2.50.40 60.000 3.52 2.50.40 60.000 32.20.20 3.52 2.50.40 60.000 32.20.20 3.52 2.50.40 60.000 32.20.20 3.52 2.50.40 60.000 32.20.20 8.21 2.02.07.000 32.22.80 4.500 3.52 2.51.6 2.2000 57 2.2.61 8.63 2.2.80 4.500 3.200 3.20.20 3.22.80 4.500 10.3000 3.20 3.20.20 3.20.20 3.1.91 8.200	Total T2DM (March 1000) T2DM (March 1000) 30 7.60 2.0000 40 7.67 2.7400 64 6.90 2.0000 18 5.59 1.1000 337	(5) E/e' ratio (5) E/e' ratio (5) E/e' ratio (7) LAVImax (7) LAVImax (8) LVMI (8) LVMI	$\begin{array}{c} -2.60 & [1.64; 3.56] & 10.3\% \\ 1.19 & [0.03; 2.35] & 8.0\% \\ -2.70 & [2.12; 3.28] & 17.6\% \\ 1.30 & [0.05; 2.55] & 7.1\% \\ -2.31 & [1.63; 2.99] & 15.4\% \\ 1.10 & [-0.12; 2.32] & 7.4\% \\ -2.38 & [1.85; 2.91] & 18.8\% \\ -3.86 & [1.18; 2.54] & 15.4\% \\ 1.86 & [1.18; 2.54] & 15.4\% \\ -3.86 & [1.18; 2.54] & 15.4\% \\ -3.87 & [2.10] & [1.72; 2.49] & 100.0\% \\ -3.87 & [2.10] & [1.72; 2.49] & 100.0\% \\ -3.87 & [2.10] & [1.72; 3.13] & 17.9\% \\ -1.00 & [-2.95] & 7.15 & 16.0\% \\ -4.70 & [-2.123; 11.83] & 17.9\% \\ -2.98 & [1.76] & (5.41) & 33.2\% \\ -11.00 & [-2.83] & (6.15) & 17.1\% \\ 6.69 & [-17.99; 31.37] & 10.5\% \\ 0.46 & [-8.74; 9.66] & 100.0\% \\ 0.66 & [-8.74; 9.66] & 100.0\% \\ 0.66 & [-3.87] & [2.77; 4.97] & 28.5\% \\ -2.60 & [-1.66; 7.06] & 6.3\% \\ -3.20 & [0.94; 5.46] & 16.5\% \\ 1.08 & [-0.24; 2.40] & 26.0\% \\ 2.58 & [1.34; 3.81] & 100.0\% \\ 6 & 5\% & C1 \\ & MD & 95\%-C1 & Weight \\ -4.60 & [1.01; 8.19] & 23.8\% \\ 4.60 & [1.01; 8.19] & 23.8\% \\ 4.5\% & 8.93 & [10.68; 17.18] & 4.5\% \\ \end{array}$
$\label{eq:changerout} \begin{split} & \text{Changerout}\\ & \text{Wangerout}\\ & \text{Wangerout}\\ & \text{Wantovani-2015}\\ & \text{Lec-2021}\\ & \text{Bonapace-2012}\\ & \text{Gu-2016}\\ & \text{Yang-2019}\\ & \text{Saluja-2019}\\ & \text{Radom effects mode}\\ & \text{Hetrogeneity:} I^2 = 46\%\\ & \text{Study}\\ & \text{Lec-2020}\\ & \text{Wantovani-2015}\\ & \text{Lec-2021}\\ & \text{Bonapace-2012}\\ & \text{Yang-2019}\\ & \text{Saluja-2019}\\ & \text{Radom effects mode}\\ & \text{Hetrogeneity:} I^2 = 47\%, *\\ & \text{Study}\\ & \text{Chang-2019}\\ & \text{Lec-2021}\\ & \text{Bonapace-2012}\\ & \text{Yang-2019}\\ & \text{Saluja-2019}\\ & \text{Radom effects mode}\\ & \text{Hetrogeneity:} I^2 = 47\%, *\\ & \text{Study}\\ & \text{Chang-2019}\\ & \text{Saluja-2019}\\ & \text{Radom effects mode}\\ & \text{Hetrogeneity:} I^2 = 62\%\\ & \text{Study}\\ & \text{Lec-2021}\\ & \text{Wang-2018}\\ & \text{Mantovani-2015}\\ & \text{Lec-2021}\\ & \text{Study-2018}\\ & \text{Mattovani-2015}\\ & \text{Lec-2021}\\ & \text{Study-2018}\\ & \text{Mattovani-2015}\\ & \text{Study-2018}\\ & \text{Mattovani-2015}\\ & \text{Lec-2021}\\ & \text{Study-2018}\\ & \text{Study-2018}\\ & Study$	Total Mean SD 67 10.20 2.7000 40 8.86 2.5400 158 9.60 2.0000 82 7.90 1.3000 60 11.10 3.3000 178 9.50 2.1100 57 9.64 1.8300 el 675 7 752.04 NAFLD 1.350 155 256.90 44.000 158 250.40 66.0000 82 210.20 37.0000 178 29.50 2.1400 178 29.50 44.000 178 250.40 66.0000 82 210.20 37.0000 178 29.12 78.000 178 29.12 78.000 178 29.12 78.000 178 29.12 78.000 178 21.26 72.200 78 1.91 8.200 178 3.108 4.500 <td>Total T2DM Mean T2DM SD 30 7.60 2.0000 40 7.67 2.7400 64 6.90 2.0000 8 9.30 3.000 18 5.59 1.1000 49 10.00 3.2000 75 7.12 1.9200 13 7.78 0.8900 337 T2M T2M 64 261.40 61.0000 64 261.40 61.0000 64 261.40 61.0000 75 262.31 62.4300 13 205.92 39.3800 469 42.14.90 5.400 75 262.31 64.000 13 27.51 2.4200 148 24.60 5.800 13 25.07 2.1900 148 24.60 5.800 13 25.07 2.1900 148 40.80 5.800 148 2.600<td>(5) E/e' ratio</td><td>$\begin{array}{c} -2.60 & [1.64; 3.56] & 10.3\% \\ 1.19 & [0.03; 2.35] & 8.0\% \\ -2.70 & [2.12; 3.28] & 17.6\% \\ 1.30 & [0.05; 2.55] & 7.1\% \\ -2.70 & [2.12; 3.28] & 17.6\% \\ 1.10 & [-0.12; 3.22] & 7.4\% \\ 1.10 & [-0.12; 3.22] & 7.4\% \\ 1.85 & [2.13] & 18.8\% \\ 1.85 & [2.14] & 18.8\% \\ 1.85 & [2.14] & 18.8\% \\ 1.86 & [1.18; 2.54] & 15.4\% \\ 1.10 & [-0.56; 1.564] & 33.2\% \\ -1.00 & [-2.05; 7.15] & 16.0\% \\ -4.70 & [-2.123; 1.183] & 17.9\% \\ -2.98 & [-7.61; 6.721] & 5.3\% \\ -11.09 & [-2.83]; 6.15] & 17.1\% \\ 6.69 & [-17.99; 31.37] & 10.5\% \\ 0.46 & [-8.74; 9.66] & 100.0\% \\ 0.66 \\ -2.60 & [-1.86; 7.06] & 6.3\% \\ -3.20 & [0.94; 5.46] & 16.5\% \\ 1.08 & [-0.24; 2.40] & 2.6\% \\ 2.58 & [1.34; 3.81] & 100.0\% \\ 6 \\ 5\% & CI) \\ \hline \begin{array}{c} MD & 95\% - CI & Weight \\ -3.87 & [2.77; 4.97] & 28.5\% \\ -3.20 & [0.94; 5.46] & 16.5\% \\ -3.80 & [-1.86; 7.18] & 4.5\% \\ 3.00 & [-3.26; 9.26] & 7.8\% \\ 4.40 & [-2.14; 1.094] & 7.2\% \\ \end{array}$</td></td>	Total T2DM Mean T2DM SD 30 7.60 2.0000 40 7.67 2.7400 64 6.90 2.0000 8 9.30 3.000 18 5.59 1.1000 49 10.00 3.2000 75 7.12 1.9200 13 7.78 0.8900 337 T2M T2M 64 261.40 61.0000 64 261.40 61.0000 64 261.40 61.0000 75 262.31 62.4300 13 205.92 39.3800 469 42.14 .90 5.400 75 262.31 64.000 13 27.51 2.4200 148 24.60 5.800 13 25.07 2.1900 148 24.60 5.800 13 25.07 2.1900 148 40.80 5.800 148 2.600 <td>(5) E/e' ratio</td> <td>$\begin{array}{c} -2.60 & [1.64; 3.56] & 10.3\% \\ 1.19 & [0.03; 2.35] & 8.0\% \\ -2.70 & [2.12; 3.28] & 17.6\% \\ 1.30 & [0.05; 2.55] & 7.1\% \\ -2.70 & [2.12; 3.28] & 17.6\% \\ 1.10 & [-0.12; 3.22] & 7.4\% \\ 1.10 & [-0.12; 3.22] & 7.4\% \\ 1.85 & [2.13] & 18.8\% \\ 1.85 & [2.14] & 18.8\% \\ 1.85 & [2.14] & 18.8\% \\ 1.86 & [1.18; 2.54] & 15.4\% \\ 1.10 & [-0.56; 1.564] & 33.2\% \\ -1.00 & [-2.05; 7.15] & 16.0\% \\ -4.70 & [-2.123; 1.183] & 17.9\% \\ -2.98 & [-7.61; 6.721] & 5.3\% \\ -11.09 & [-2.83]; 6.15] & 17.1\% \\ 6.69 & [-17.99; 31.37] & 10.5\% \\ 0.46 & [-8.74; 9.66] & 100.0\% \\ 0.66 \\ -2.60 & [-1.86; 7.06] & 6.3\% \\ -3.20 & [0.94; 5.46] & 16.5\% \\ 1.08 & [-0.24; 2.40] & 2.6\% \\ 2.58 & [1.34; 3.81] & 100.0\% \\ 6 \\ 5\% & CI) \\ \hline \begin{array}{c} MD & 95\% - CI & Weight \\ -3.87 & [2.77; 4.97] & 28.5\% \\ -3.20 & [0.94; 5.46] & 16.5\% \\ -3.80 & [-1.86; 7.18] & 4.5\% \\ 3.00 & [-3.26; 9.26] & 7.8\% \\ 4.40 & [-2.14; 1.094] & 7.2\% \\ \end{array}$</td>	(5) E/e' ratio	$\begin{array}{c} -2.60 & [1.64; 3.56] & 10.3\% \\ 1.19 & [0.03; 2.35] & 8.0\% \\ -2.70 & [2.12; 3.28] & 17.6\% \\ 1.30 & [0.05; 2.55] & 7.1\% \\ -2.70 & [2.12; 3.28] & 17.6\% \\ 1.10 & [-0.12; 3.22] & 7.4\% \\ 1.10 & [-0.12; 3.22] & 7.4\% \\ 1.85 & [2.13] & 18.8\% \\ 1.85 & [2.14] & 18.8\% \\ 1.85 & [2.14] & 18.8\% \\ 1.86 & [1.18; 2.54] & 15.4\% \\ 1.86 & [1.18; 2.54] & 15.4\% \\ 1.86 & [1.18; 2.54] & 15.4\% \\ 1.86 & [1.18; 2.54] & 15.4\% \\ 1.86 & [1.18; 2.54] & 15.4\% \\ 1.86 & [1.18; 2.54] & 15.4\% \\ 1.10 & [-0.56; 1.564] & 33.2\% \\ -1.00 & [-2.05; 7.15] & 16.0\% \\ -4.70 & [-2.123; 1.183] & 17.9\% \\ -2.98 & [-7.61; 6.721] & 5.3\% \\ -11.09 & [-2.83]; 6.15] & 17.1\% \\ 6.69 & [-17.99; 31.37] & 10.5\% \\ 0.46 & [-8.74; 9.66] & 100.0\% \\ 0.66 \\ -2.60 & [-1.86; 7.06] & 6.3\% \\ -3.20 & [0.94; 5.46] & 16.5\% \\ 1.08 & [-0.24; 2.40] & 2.6\% \\ 2.58 & [1.34; 3.81] & 100.0\% \\ 6 \\ 5\% & CI) \\ \hline \begin{array}{c} MD & 95\% - CI & Weight \\ -3.87 & [2.77; 4.97] & 28.5\% \\ -3.20 & [0.94; 5.46] & 16.5\% \\ -3.20 & [0.94; 5.46] & 16.5\% \\ -3.20 & [0.94; 5.46] & 16.5\% \\ -3.20 & [0.94; 5.46] & 16.5\% \\ -3.20 & [0.94; 5.46] & 16.5\% \\ -3.20 & [0.94; 5.46] & 16.5\% \\ -3.20 & [0.94; 5.46] & 16.5\% \\ -3.20 & [0.94; 5.46] & 16.5\% \\ -3.80 & [-1.86; 7.18] & 4.5\% \\ 3.00 & [-3.26; 9.26] & 7.8\% \\ 4.40 & [-2.14; 1.094] & 7.2\% \\ \end{array}$
Chang=2019 Wang=2018 Mantovani=2015 Lee=2021 Bonapace=2012 Gu=2016 Yang=2019 Random effects mode Heterogeneity: $I^2 = 46\%$ Study Lee=2020 Mantovani=2015 Lee=2021 Bonapace=2012 Yang=2019 Random effects model Heterogeneity: $I^2 = 47\%$, $I^2 = 62\%$ Study Lee=2019 Random effects model Heterogeneity: $I^2 = 62\%$ Study Lee=2021 Bonapace=2012 Wang=2018 Mantovani=2015 Lee=2021 Bonapace=2012 Wang=2020	Total Mean SD 67 10.20 2.7000 40 8.86 2.5400 158 9.60 2.0000 81 16.63 3.000 81 16.63 3.000 178 9.50 2.1100 57 9.64 1.8300 el 675 5.64 750 9.64 1.8300 el 675 7.64 158 256.09 44.000 158 256.09 44.000 158 256.09 44.000 178 29.10 27.000 32 28.20 78.000 32 28.20 78.000 32 28.20 78.000 178 29.12 74.00 32 28.20 78.000 32 28.20 44.000 178 29.14 8.200 32 29.20 4.500 32 21.26 8.200 <	Total T2DM Mean T2DM SD 30 7.60 2.0000 40 7.67 2.7400 64 6.90 2.0000 8 9.30 3.000 18 5.59 1.1000 49 10.00 3.2000 75 7.12 1.9200 13 7.78 0.8900 337 T2M T2M 64 261.40 61.0000 64 261.40 61.0000 64 261.40 61.0000 75 262.31 62.4300 13 205.92 39.3800 469 42.14.90 5.400 13 25.07 2.1900 148 24.80 5.800 18 24.80 5.800 13 25.07 2.1900 148 24.80 5.800 13 25.07 2.1900 148 14.80 5.800 148 16.5300 <td>(5) E/e' ratio</td> <td>$\begin{array}{c} -2.60 & [1.64; 3.56] & 10.3\% \\ 1.19 & [0.03; 2.35] & 8.0\% \\ -2.70 & [2.12; 3.28] & 17.6\% \\ -2.70 & [2.12; 3.28] & 17.6\% \\ -2.31 & [1.63; 2.99] & 15.4\% \\ 1.10 & [-0.12; 2.22] & 7.4\% \\ -2.38 & [1.85; 2.21] & 18.8\% \\ 1.86 & [1.18; 2.34] & 15.4\% \\ 2.38 & [1.85; 2.34] & 18.8\% \\ 1.86 & [1.18; 2.34] & 15.4\% \\ 2.10 & [1.72; 2.49] & 100.0\% \\ 3 \\ 3^{5\%} \text{ CI} \\ \end{array}$</td>	(5) E/e' ratio	$\begin{array}{c} -2.60 & [1.64; 3.56] & 10.3\% \\ 1.19 & [0.03; 2.35] & 8.0\% \\ -2.70 & [2.12; 3.28] & 17.6\% \\ -2.70 & [2.12; 3.28] & 17.6\% \\ -2.31 & [1.63; 2.99] & 15.4\% \\ 1.10 & [-0.12; 2.22] & 7.4\% \\ -2.38 & [1.85; 2.21] & 18.8\% \\ 1.86 & [1.18; 2.34] & 15.4\% \\ 2.38 & [1.85; 2.34] & 18.8\% \\ 1.86 & [1.18; 2.34] & 15.4\% \\ 2.10 & [1.72; 2.49] & 100.0\% \\ 3 \\ 3^{5\%} \text{ CI} \\ \end{array}$
Chang=2019 Wang=2018 Manitovani-2015 Lee=2021 Bonapace=2012 Git=2016 Yang=2019 Random effects model Heterogeneity: $P^2 = 469^{-10}^{-1$	Total Mean SD 67 10.20 2.7000 40 8.86 2.5400 158 9.60 2.0000 83 10.60 3.200 32 7.90 1.3000 60 11.01 3.300 61 11.01 3.300 62 7.9.64 1.8300 61 1.10 3.300 61 1.10 3.300 62 5.7 9.64 1.8300 61 3.55 2.60 4.4000 158 2.50 4.4000 158 152 2.50 4.4000 158 152 2.50 4.4000 158 152 2.61 2.300 57 72.12 61 47.3400 863 82 2.280 4.500 32 178 3.12 2.860 4.500 32 2.80 4.500 32 178 1.82	Total T2DM (March Mean T2DM SN 30 7.60 2.0000 40 7.67 2.7400 64 6.90 2.0000 18 5.59 1.1000 19 10.00 3.2000 75 7.12 1.9200 337	(5) E/e' ratio	$\begin{array}{c c c c c c c c c c c c c c c c c c c $
Chang=2019 Wang=2018 Manitovani-2015 Lee=2021 Bonapace=2012 Git=2016 Yang=2019 Random effects model Heterogeneity: $I^2 = 469$ Study Lee=2020 Mantovani=2015 Lee=2021 Bonapace=2012 Yang=2019 Random effects model Heterogeneity: $I^2 = 47\%$, t^2 Study Chang=2019 Random effects model Heterogeneity: $I^2 = 62\%$ Study Lee=2021 Bonapace=2012 Yang=2019 Random effects model Heterogeneity: $I^2 = 62\%$ Study Lee=2021 Bonapace=2012 Yang=2018 Random effects model Heterogeneity: $I^2 = 62\%$ Study Lee=2021 Bonapace=2012 Yang=2018 Study Lee=2020 Wang=2018 Kandom effects model Study Lee=2021 Bonapace=2012 Yang=2019 Random effects model Study Lee=2021 Bonapace=2012 Yang=2018 Yang=2019 Random effects model Yang=2019 Yang=2019 Random effects model Yang=2019 Yang=2019 Yang=2019 Yang=2019 Random effects model Yang=2019 Yang=2019 Random effects model Yang=2019 Yang=2019 Yang=2019 Yang=2019 Random effects model Yang=2019 Yang=2019 Yang=2019 Yang=2019 Random effects model Yang=2019 Yang=20	Total Mean SD 67 10.20 2.7000 40 8.86 2.5400 158 9.60 2.0000 83 10.60 3.2000 83 10.60 3.2000 9.79 1.3000 60 11 10.3 3.000 178 9.50 2.1100 757 9.64 1.8300 el 675 5.7 5., $\tau^2 = 0.1301, p = 0.07$ 70000 355 250.40 66<0000	Total T2DM Mean T2DM SD 30 7.60 2.0000 40 7.67 2.7400 64 6.90 2.0000 78 9.30 3.000 18 5.59 1.1000 49 10.00 3.2000 75 7.12 1.9200 13 7.78 0.8900 337 W Value Value 42 14.90 1.2000 64 261.40 61.0000 64 261.40 61.0000 75 262.31 2.0400 18 2.05 2.4800 75 2.62.31 2.4900 13 2.05.92 39.3800 46 Value 13 2.72.1 2.4200 13 2.5.07 2.1900 148 24.60 4.6000 13 2.5.07 2.1900 148 <td>(5) E/e' ratio</td> <td>$\begin{array}{c} -2.60 & [1.64; 3.56] & 10.3\% \\ 1.19 & [0.03; 2.35] & 8.0\% \\ -2.70 & [2.12; 3.28] & 17.6\% \\ 1.30 & [0.05; 2.55] & 7.1\% \\ -2.31 & [1.63; 2.99] & 15.4\% \\ 1.10 & [-0.12; 2.32] & 7.4\% \\ -2.38 & [1.85; 2.91] & 18.8\% \\ -3.86 & [1.18; 2.54] & 15.4\% \\ 1.10 & [-0.12; 2.32] & 7.4\% \\ -3.86 & [1.18; 2.54] & 15.4\% \\ -3.86 & [1.18; 2.54] & 15.4\% \\ -3.86 & [1.18; 2.54] & 15.4\% \\ -3.87 & [2.10] & [1.72; 2.49] & 100.0\% \\ -3.87 & [2.73, 49] & 100.0\% \\ -4.70 & [-2.123; 11.83] & 17.9\% \\ -2.98 & [-7.61; 6.72] & 15.3\% \\ -11.00 & [-2.93; 3.137] & 10.5\% \\ 0.46 & [-8.74; 9.66] & 100.0\% \\ 0.66 & [-7.99; 31.37] & 10.5\% \\ 0.46 & [-8.74; 9.66] & 100.0\% \\ 0.66 & [-3.20] & [0.58; 3.82] & 22.6\% \\ -2.60 & [-1.66; 7.06] & 6.3\% \\ -3.20 & [0.94; 5.46] & 16.5\% \\ -3.89 & [0.68; 17.18] & 4.5\% \\ 3.00 & [-3.26; 9.26] & 7.8\% \\ 4.40 & [-1.41; 10.94] & 7.2\% \\ 4.90 & [-4.48; 14.28] & 3.5\% \\ 4.90 & [-4.48; 14.28] & 3.5\% \\ 1.90 & [-0.44; 8.44] & 2.3\% \\ 3.00 & [-6.14; 8.14] & 10.0\% \\ 2.90 & [-2.74; 8.54] & 9.7\% \\ \end{array}$</td>	(5) E/e' ratio	$\begin{array}{c} -2.60 & [1.64; 3.56] & 10.3\% \\ 1.19 & [0.03; 2.35] & 8.0\% \\ -2.70 & [2.12; 3.28] & 17.6\% \\ 1.30 & [0.05; 2.55] & 7.1\% \\ -2.31 & [1.63; 2.99] & 15.4\% \\ 1.10 & [-0.12; 2.32] & 7.4\% \\ -2.38 & [1.85; 2.91] & 18.8\% \\ -3.86 & [1.18; 2.54] & 15.4\% \\ 1.10 & [-0.12; 2.32] & 7.4\% \\ -3.86 & [1.18; 2.54] & 15.4\% \\ -3.86 & [1.18; 2.54] & 15.4\% \\ -3.86 & [1.18; 2.54] & 15.4\% \\ -3.87 & [2.10] & [1.72; 2.49] & 100.0\% \\ -3.87 & [2.73, 49] & 100.0\% \\ -4.70 & [-2.123; 11.83] & 17.9\% \\ -2.98 & [-7.61; 6.72] & 15.3\% \\ -11.00 & [-2.93; 3.137] & 10.5\% \\ 0.46 & [-8.74; 9.66] & 100.0\% \\ 0.66 & [-7.99; 31.37] & 10.5\% \\ 0.46 & [-8.74; 9.66] & 100.0\% \\ 0.66 & [-3.20] & [0.58; 3.82] & 22.6\% \\ -2.60 & [-1.66; 7.06] & 6.3\% \\ -3.20 & [0.94; 5.46] & 16.5\% \\ -3.20 & [0.94; 5.46] & 16.5\% \\ -3.20 & [0.94; 5.46] & 16.5\% \\ -3.20 & [0.94; 5.46] & 16.5\% \\ -3.20 & [0.94; 5.46] & 16.5\% \\ -3.89 & [0.68; 17.18] & 4.5\% \\ 3.00 & [-3.26; 9.26] & 7.8\% \\ 4.40 & [-1.41; 10.94] & 7.2\% \\ 4.90 & [-4.48; 14.28] & 3.5\% \\ 4.90 & [-4.48; 14.28] & 3.5\% \\ 1.90 & [-0.44; 8.44] & 2.3\% \\ 3.00 & [-6.14; 8.14] & 10.0\% \\ 2.90 & [-2.74; 8.54] & 9.7\% \\ \end{array}$
$\label{eq:constraint} \begin{array}{l} \label{eq:constraint} Chang=2019 \\ \mbox{Wang=2018} \\ \mbox{Wanizvaria} 2015 \\ \mbox{Lec=2021} \\ \mbox{Bonapace-2012} \\ \mbox{Guius=2019} \\ \mbox{Bonapace-2019} \\ \mbox{Study} \\ \mbox{Lec=2020} \\ \mbox{Mantovani=2015} \\ \mbox{Lec=2021} \\ \mbox{Bonapace-2012} \\ \mbox{Yang=2019} \\ \mbox{Study} \\ \mbox{Chang=2019} \\ \mbox{Bonapace-2012} \\ \mbox{Yang=2019} \\ \mbox{Study} \\ \mbox{Chang=2019} \\ \mbox{Bonapace-2012} \\ \mbox{Yang=2019} \\ \mbox{Study} \\ \mbox{Chang=2019} \\ \mbox{Bonapace-2012} \\ \mbox{Yang=2019} \\ \mbox{Bonapace-2012} \\ \mbox{Yang=2019} \\ \mbox{Bonapace-2012} \\ \mbox{Yang=2018} \\ \mbox{Mantovani=2015} \\ \mbox{Lec=2021} \\ \mbox{Bonapace-2012} \\ \mbox{Wang=2018} \\ \mbox{Mantovani=2015} \\ \mbox{Lec=2021} \\ \mbox{Bonapace-2012} \\ \mbox{Wang=2018} \\ \mbox{Mantovani=2015} \\ \mbox{Lec=2021} \\ \mbox{Bonapace-2012} \\ \mbox{Wang=2019} \\ \mbox{Study} \\ \mbox{Lec=2021} \\ \mbox{Bonapace-2012} \\ \mbox{Wang=2018} \\ \mbox{Mantovani=2015} \\ \mbox{Lec=2021} \\ \mbox{Wang=2019} \\ Wa$	Total Mean SD 67 10.20 2.7000 40 8.86 2.5400 158 9.60 2.0000 83 10.60 3.2000 83 10.60 3.2000 9.79 1.3000 60 11 10.3 3.000 178 9.50 2.1100 757 9.64 1.8300 el 675 5.7 5., $\tau^2 = 0.1301, p = 0.07$ 70000 355 250.40 66<0000	Total Mean T2DM SN SN Total Mean T2DM SN SN SN SN SN SN SN SN SN SN SN SN SN	(5) E/e' ratio	$\begin{array}{c} -2.60 & [1.64; 3.56] & 10.3\% \\ 1.19 & [0.03; 2.35] & 8.0\% \\ -2.70 & [2.12; 3.28] & 17.6\% \\ 1.30 & [0.03; 2.55] & 7.1\% \\ 1.10 & [-0.12; 3.22] & 17.6\% \\ 1.10 & [-0.12; 3.22] & 15.4\% \\ 1.10 & [-0.12; 3.22] & 15.4\% \\ 1.10 & [-0.12; 3.22] & 7.4\% \\ 1.86 & [1.18; 2.54] & 15.4\% \\ 2.38 & [1.85; 2.91] & 18.8\% \\ 1.86 & [1.18; 2.54] & 15.4\% \\ 2.10 & [1.72; 2.49] & 100.0\% \\ 3 \\ 3 \\ 3\% \\ CI) \\ \end{array}$

Figure 2 The forest plot for each diastolic-dysfunction-related echocardiographic parameters. e', mean mitral annular diastolic velocity; LAVImax, left atrial maximum volume index; LVMI, left ventricular mass index; MD, mean difference; NAFLD, non-alcoholic fatty liver disease; T2DM, type 2 diabetes mellitus.

14 is the gray zone of the E/e' ratio, and whether the pressure is elevated with other parameters must be determined with caution, it is highly specific when the ratio is greater than 14.¹⁵

The left atrium functions as a blood reservoir, conduit, and booster pump during cardiac circulation and is closely related to LV early diastolic function. In addition to the cumulative effect of increasing LV filling pressure over time, prominent evidence of LVDD diagnosis was also observed in LA volume.^{15 37} As one of the parameters recommended by ASE for evaluating LVDD, LAVImax was found to be significantly greater in the T2DM with NAFLD group in our study. In addition, LV mass has been found to be an early marker of LVDD and a powerful predictor of increased HF risk.^{38 39} Although LVM is an indicator used to measure cardiac structure, it is still advocated as an essential supplementary index to evaluate diastolic dysfunction in ASE/EACVI guidelines.¹⁵ Moreover, DM directly leads to increased LVM and consequently affects diastolic function, which is also a process in DCM.^{40 41} It is believed that the increase in LVM in patients with T2DM is a clinical practice issue of great need to be addressed.³⁸ Sensitivity analysis showed that the results of parameters with statistical differences were stable, indicating the reliable effect of our metaanalysis result that NAFLD is associated with an increased risk of LVDD. Interestingly, the underlying mechanism of this phenomenon is worth speculation.

Multiple well-known epidemiological trials have confirmed the link between DM and HF,^{5 42} and the presence of DM could lead to a 33% higher risk of hospitalizations for HF (adjusted OR: 1.33; 95% CI: 1.18 to 1.50).⁴³ DM might be a traditional CVD risk factor that mediates the occurrence of HF. Otherwise, it could be the only perpetrator of DCM. Despite the fact that DCM is an abnormality of cardiac structure and function, of which diagnosis requires the exclusion of coronary artery disease and hypertension, the natural augmentation of DM on ventricular dysfunction is persistent. Therefore, DCM is an indispensable factor in HF research to describe the vulnerability of the myocardium to dysfunction.²⁴⁴

DM-related glucose and lipid metabolism disorders can induce DCM, triggering oxidative stress and inflammation via different signaling pathways.² Hyperglycemia plays an essential role in the pathogenesis of DCM, activating a series of pathological changes or processes such as lipotoxicity, cardiomyocyte apoptosis, and myocardial fibrosis.^{45–47} Under diabetic conditions, the heart is exposed to an environment of excessive fatty acids, which results in the accumulation of metabolic intermediates and by-products, eventually manifesting as cardiac steatosis.^{48–50} Thus, DCM can also be regarded as a lipidstorage disease.

Although there is currently no consensus on the pathological mechanisms of DCM, DM can independently induce an absolute or relative increase in LV mass, resulting in LV hypertrophy that progressively affects diastolic ventricular filling, isovolumetric relaxation, and LV end-diastolic pressure.^{40 41} This initial phase, accompanied by subtle symptoms, has the potential to progress to HFpEF and eventually lead to HF with reduced ejection fraction (HFrEF), another phenotype of HF dominated by systolic dysfunction.⁵¹ HFpEF accounts for a large proportion, with approximately 30%–50% of HF cases in DM,⁴⁷ which have more severe clinical outcomes than HFrEF, manifesting as increased LV mass and reduced LV diastolic distensibility.^{52 53}

The European Society of Cardiology proposed that the diagnosis of HFpEF should meet the requirements of LVEF greater than 50% with evidence of diastolic dysfunction.⁵⁴ LVDD results from impaired myocardium relaxation ability leading to decreased left ventricular flexibility, which is considered the main contributing factor for the development of HFpEF and the first sign of cardiac function abnormality in patients with T2DM.^{55,56}

Lipid metabolism is a major contributor to ventricular function. NAFLD is a metabolic-dysfunction-related liver disease that occurs without excessive alcohol consumption (women: less than 20 g/day; men: less than 30 g/day), including steatosis, fatty infiltration, inflammation (non-alcoholic steatohepatitis), fibrosis, and ultimately cirrhosis.⁵⁷ In the past few years, it has been increasingly recognized that NAFLD can also affect the extrahepatic system, and its relationship with T2DM is bidirectional. T2DM might accelerate the development of NAFLD from steatosis to non-alcoholic steatohepatitis, cirrhosis, and even hepatocellular carcinoma, whereas the presence of NAFLD would induce poor glycemic control in patients with T2DM.⁵⁸ Emerging evidence suggests that NAFLD is a hallmark of ectopic fat accumulation in the myocardium, and a significant positive correlation of fat content could be observed between intramyocardial and intrahepatic.^{25 59 60} Myocardial lipid accumulation is due to increased free fatty acids, which influence LV diastolic function.^{61 62} Furthermore, sufficient findings point out that the dysregulated secretion of proinflammatory cytokines and hepatokines in the progression of NAFLD promotes inflammation and oxidative stress in the myocardial tissue and manifests as cardiac dysfunction.⁶³ However, the exact pathophysiological mechanisms that connect NAFLD to LVDD remain unclear. NAFLD is likely a part of the pathogenesis associated with DM augmentation of diastolic dysfunction, leading to abnormal cardiac structure and function rather than just a simple accompanying symptom or a target organ of this cardiac pathological alteration.

Most of the patients with DM who present with diastolic dysfunction have an insidious clinical asymptomatic period, and many of them remain under no assessment and treatment of LV diastolic function because symptom onset rarely occurs in the initial stage. Identifying T2DM patients with NAFLD at an early stage can provide early warning of their risk of developing LVDD and even HFpEF. Our study demonstrated that NAFLD is associated with LVDD risk in the T2DM population. Although causality cannot be established owing to the

Cardiovascular and metabolic risk

lack of longitudinal study evidence, it is still a relatively early warning approach for screening patients at higher risk and improving their prognosis, as myocardial injury precedes the development of cardiac dysfunction that can be observed by a reliable diagnostic technique.

Admittedly, our meta-analysis has some limitations. First, all of these included studies were cross-sectional in design, which inevitably led to the inability to demonstrate the causality of NAFLD with an increased risk of LVDD in the T2DM population. Second, owing to the small number of original studies, stratification analysis could not be performed in our study. Third, several echocardiographic parameters in our study had moderate heterogeneity; therefore, we used random-effects models instead of fixed-effects models, which could produce more reliable estimates.⁶⁴ In addition, most of the individuals in the original studies were registered in Asia, so the interpretation of the results needs to be done with caution, and further high-quality studies are required.

CONCLUSIONS

This systematic review and meta-analysis found that NAFLD is associated with an increased risk of LVDD in the T2DM population. When NAFLD is diagnosed in patients with diabetes, routine echocardiography should be performed to assess the cardiac diastolic impairment. This first step needs to be further confirmed in prospective cohort studies. Identifying serum or plasma biomarkers with high specificity that could more accurately reflect the risk of LVDD in patients with T2DMshould be pursued in the future.

Acknowledgements We would like to thank Editage (www.editage.cn) for English language editing.

Contributors SW designed the study protocol and wrote the first draft of the manuscript. XZ and QZ extracted the data, performed analyses, and interpreted the data. BZ and LZ contributed to the polishing and revision of the manuscript, supervised the study, and resolved all discrepancies. All authors revised the manuscript critically and approved the final version of the manuscript. SW is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding This research was funded by the Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences (Cl2021A01605); the Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine (ZYYCXTD-D-202001); the National Key Research and Development Program of China (2019YFC1709904); the National Natural Science Foundation of China (82104835); and the China Postdoctoral Science Foundation (2021M693542).

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines,

terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Sicheng Wang http://orcid.org/0000-0003-3427-773X

REFERENCES

- 1 International Diabetes Federation. *IDF diabetes atlas.* 10th ed. Brussels: International Diabetes Federation, 2021.
- 2 Tan Y, Zhang Z, Zheng C, et al. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol 2020;17:585–607.
- 3 Abudureyimu M, Luo X, Wang X, et al. Heart failure with preserved ejection fraction (hfpef) in type 2 diabetes mellitus: from pathophysiology to therapeutics. J Mol Cell Biol 2022;14:mjac028.
- 4 Jankauskas SS, Kansakar U, Varzideh F, et al. Heart failure in diabetes. Metabolism 2021;125:154910.
- 5 Thrainsdottir IS, Aspelund T, Thorgeirsson G, et al. The association between glucose abnormalities and heart failure in the populationbased reykjavik study. *Diabetes Care* 2005;28:612–6.
- 6 Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. *Am J Cardiol* 1974;34:29–34.
- 7 Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American heart association and the heart failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. *Circulation* 2019;140:e294–324.
- 8 Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972;30:595–602.
- 9 Aneja A, Tang WHW, Bansilal S, et al. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 2008;121:748–57.
- 10 Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016;64:73–84.
- 11 Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. *Nat Rev Endocrinol* 2022;18:525–39.
- 12 Sert A, Aypar E, Pirgon O, et al. Left ventricular function by echocardiography, tissue Doppler imaging, and carotid intima-media thickness in obese adolescents with nonalcoholic fatty liver disease. Am J Cardiol 2013;112:436–43.
- 13 Yong JN, Ng CH, Lee CW-M, et al. Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis. *Hepatol Int* 2022;16:269–81.
- 14 Azzam H, Malnick S. Non-alcoholic fatty liver disease the heart of the matter. World J Hepatol 2015;7:1369–76.
- Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the american society of echocardiography and the european association of cardiovascular imaging. J Am Soc Echocardiogr 2016;29:277–314.
 Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of
- 16 Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000;283:2008–12.
- 17 Rostom A, Dubé C, Cranney A, et al. Appendix D. quality assessment forms: cross-sectional/prevalence study quality, (evidencereports/technology assessments, no. 104). In: *Celiac Disease*. Rockville (MD): Agency for Healthcare Research and Quality (US), 2004. Available: https://www.ncbi.nlm.nih.gov/books/ NBK35156/
- 18 Luo D, Wan X, Liu J, *et al.* Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. *Stat Methods Med Res* 2018;27:1785–805.
- 19 Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014;14:135.
- 20 Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.

6

- 21 Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. *BMJ* 1997;315:1533–7.
- 22 Mantovani A, Pernigo M, Bergamini C, et al. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. *PLoS One* 2015;10:e0135329.
- 23 Lee M, Kim KJ, Chung T-H, et al. Nonalcoholic fatty liver disease, diastolic dysfunction, and impaired myocardial glucose uptake in patients with type 2 diabetes. *Diabetes Obes Metab* 2021;23:1041–51.
- 24 Chang W, Wang Y, Sun L, et al. Evaluation of left atrial function in type 2 diabetes mellitus patients with nonalcoholic fatty liver disease by two-dimensional speckle tracking echocardiography. *Echocardiography* 2019;36:1290–7.
- 25 Bonapace S, Perseghin G, Molon G, et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. *Diabetes Care* 2012;35:389–95.
- 26 Gu L, Yao L, Wang Y, et al. Association between cardiac dysfunction and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus [In Chinese with English abstract]. *Chin J Diabetes Mellitus* 2016;8:541–7.
- 27 Wang Q, Ma W, Xia J. Nonalcoholic fatty liver is associated with further left ventricular abnormalities in patients with type 2 diabetes mellitus: a 3-dimensional speckle-tracking study. *J Ultrasound Med* 2018;37:1899–911.
- 28 Lee H, Kim G, Choi YJ, et al. Association between non-alcoholic steatohepatitis and left ventricular diastolic dysfunction in type 2 diabetes mellitus. *Diabetes Metab J* 2020;44:267–76.
- 29 Yang X, Luo A, Gao X. Evaluation of the characteristics of cardiac function changes in T2DM patients with NAFLD by echocardiography and tissue doppler imaging [In Chinese with English abstract]. *Practical Journal of Clinical Medicine* 2019;16:33–6.
- 30 Wang D, Li J, Li L, *et al*. The relationship between homocysteine and cardiac diastolic function in patients of type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease [In Chinese with English abstract]. *Tianjin Medical Journal* 2020;48:1106–9.
- 31 Saluja M, Kumar K, Swami YK, et al. Association between non- alcoholic fatty liver disease and left ventricular diastolic dysfunction in patients of type 2 diabetes. J Assoc Physicians India 2019;67:20–4. Available: https://japi.org/q2e4c464/associationbetween-non-alcoholic-fatty-liver-disease-and-left-ventriculardiastolic-dysfunction-in-patients-of-type-2-diabetes
- 32 Ma RCW. Epidemiology of diabetes and diabetic complications in China. *Diabetologia* 2018;61:1249–60.
- 33 Fischer M, Baessler A, Hense HW, et al. Prevalence of left ventricular diastolic dysfunction in the community. results from a doppler echocardiographic-based survey of a population sample. Eur Heart J 2003;24:320–8.
- 34 Bella JN, Palmieri V, Roman MJ, et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middleaged and elderly adults: the strong heart study. *Circulation* 2002;105:1928–33.
- 35 Cazzaniga M, Salerno F, Pagnozzi G, et al. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. *Gut* 2007;56:869–75.
- 36 Zhyvotovska A, Yusupov D, Kamran H, et al. Diastolic dysfunction in patients with chronic obstructive pulmonary disease: a metaanalysis of case controlled studies. Int J Clin Res Trials 2019;4:137.
- 37 Okamatsu K, Takeuchi M, Nakai H, et al. Effects of aging on left atrial function assessed by two-dimensional speckle tracking echocardiography. J Am Soc Echocardiogr 2009;22:70–5.
- 38 Ida S, Kaneko R, Murata K. Effects of oral antidiabetic drugs on left ventricular mass in patients with type 2 diabetes mellitus: a network meta-analysis. *Cardiovasc Diabetol* 2018;17:129.
- 39 Seferovic JP, Tesic M, Seferovic PM, et al. Increased left ventricular mass index is present in patients with type 2 diabetes without ischemic heart disease. Sci Rep 2018;8:926.
- 40 Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. *Rev Endocr Metab Disord* 2010;11:31–9.
- 41 Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. *Circ Res* 2018;122:624–38.
- 42 Suskin N, McKelvie RS, Burns RJ, et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. *Eur Heart J* 2000;21:1368–75.

- 43 Cavender MA, Steg PG, Smith SC Jr, *et al.* Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the reduction of atherothrombosis for continued health (reach) registry. *Circulation* 2015;132:923–31.
- 44 Kenny HC, Abel ED. Heart failure in type 2 diabetes mellitus. *Circ Res* 2019;124:121–41.
- 45 Wang S, Tian C, Gao Z, *et al*. Research status and trends of the diabetic cardiomyopathy in the past 10 years (2012-2021): a bibliometric analysis. *Front Cardiovasc Med* 2022;9:1018841.
- 46 van de Weijer T, Schrauwen-Hinderling VB, Schrauwen P. Lipotoxicity in type 2 diabetic cardiomyopathy. *Cardiovasc Res* 2011;92:10–8.
- 47 Teupe C, Rosak C. Diabetic cardiomyopathy and diastolic heart failure -- difficulties with relaxation. *Diabetes Res Clin Pract* 2012;97:185–94.
- 48 Sharma S, Adrogue JV, Golfman L, et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 2004;18:1692–700.
- 49 Rijzewijk LJ, van der Meer RW, Lamb HJ, et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 2009;54:1524–32.
- 50 Nakamura M, Sadoshima J. Cardiomyopathy in obesity, insulin resistance and diabetes. J Physiol 2020;598:2977–93.
- 51 Murtaza G, Virk HUH, Khalid M, et al. Diabetic cardiomyopathy-a comprehensive updated review. Prog Cardiovasc Dis 2019;62:315–26.
- 52 MacDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. *Eur Heart J* 2008;29:1377–85.
- 53 Paulus WJ, Dal Canto E. Distinct myocardial targets for diabetes therapy in heart failure with preserved or reduced ejection fraction. *JACC Heart Fail* 2018;6:1–7.
- 54 Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the heart failure Society of America, heart failure association of the European Society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure: endorsed by the Canadian heart failure society, heart failure association of India, cardiac Society of Australia and New Zealand, and Chinese heart failure association. Eur J Heart Fail 2021;23:352–80.
- 55 Lam CSP, Roger VL, Rodeheffer RJ, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. *Circulation* 2007;115:1982–90.
- 56 Boyer JK, Thanigaraj S, Schechtman KB, et al. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 2004;93:870–5.
- 57 Anstee QM, McPherson S, Day CP. How big a problem is nonalcoholic fatty liver disease? *BMJ* 2011;343:bmj.d3897.
- 58 Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. *Nat Rev Gastroenterol Hepatol* 2013;10:330–44.
- 59 Ng ACT, Delgado V, Bertini M, *et al*. Myocardial steatosis and biventricular strain and strain rate imaging in patients with type 2 diabetes mellitus. *Circulation* 2010;122:2538–44.
- 60 Turan Y. The nonalcoholic fatty liver disease fibrosis score is related to epicardial fat thickness and complexity of coronary artery disease. *Angiology* 2020;71:77–82.
- 61 Boden G. Obesity, insulin resistance and free fatty acids. *Curr Opin Endocrinol Diabetes Obes* 2011;18:139–43.
- 62 Kankaanpää M, Lehto H-R, Pärkkä JP, et al. Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. J Clin Endocrinol Metab 2006;91:4689–95.
- 63 Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. *N Engl J Med* 2010;363:1341–50.
- 64 Tufanaru C, Munn Z, Stephenson M, et al. Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. Int J Evid Based Healthc 2015;13:196–207.